Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gary T Ferguson

Showing results (61-70 of 103) with videos related to

Pageof 11
Sort By:
Lung|October 11, 2017
Dual Bronchodilation with Indacaterol Maleate/Glycopyrronium Bromide Compared with Umeclidinium Bromide/Vilanterol in Patients with Moderate-to-Severe COPD: Results from Two Randomized, Controlled, Cross-over StudiesEdward Kerwin, Gary T Ferguson, Shahin Sanjar, et al.
International Journal of Chronic Obstructive Pulmonary Disease|April 10, 2019
AMPLIFY: a randomized, Phase III study evaluating the efficacy and safety of aclidinium/formoterol vs monocomponents and tiotropium in patients with moderate-to-very severe symptomatic COPDSanjay Sethi, Edward Kerwin, Henrik Watz, et al.
Respiratory Research|December 14, 2011
Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trialAnthony D'Urzo, Gary T Ferguson, Jan A van Noord, et al.
Journal of Asthma and Allergy|December 19, 2019
Two-Year Integrated Efficacy And Safety Analysis Of Benralizumab In Severe AsthmaJ Mark FitzGerald, Eugene R Bleecker, Arnaud Bourdin, et al.
COPD|October 30, 2009
Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomesAntonio Anzueto, Gary T Ferguson, Greg Feldman, et al.
Advances in Therapy|April 30, 2021
Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol Fumarate versus Other Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysisArnaud Bourdin, Nicolas Molinari, Gary T Ferguson, et al.
Journal of Managed Care & Specialty Pharmacy|May 3, 2023
Clinical and economic outcomes in patients with chronic obstructive pulmonary disease initiating maintenance therapy with tiotropium bromide/olodaterol or fluticasone furoate/umeclidinium/vilanterolSanjay Sethi, Swetha R Palli, Lindsay G S Bengtson, et al.
The New England Journal of Medicine|February 23, 2007
Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary diseasePeter M A Calverley, Julie A Anderson, Bartolome Celli, et al.
Chest|January 23, 2018
β-Blockers in COPD: A Cohort Study From the TONADO Research ProgramFrançois Maltais, Roland Buhl, Andrea Koch, et al.
Respiratory Medicine|June 25, 2021
Benefits of budesonide/glycopyrrolate/formoterol fumarate (BGF) on symptoms and quality of life in patients with COPD in the ETHOS trialFernando J Martinez, Klaus F Rabe, Gary T Ferguson, et al.
Pageof 11

Showing results (61-70 of 103) with videos related to

Sort By:
Pageof 11
Lung|October 11, 2017
Dual Bronchodilation with Indacaterol Maleate/Glycopyrronium Bromide Compared with Umeclidinium Bromide/Vilanterol in Patients with Moderate-to-Severe COPD: Results from Two Randomized, Controlled, Cross-over StudiesEdward Kerwin, Gary T Ferguson, Shahin Sanjar, et al.
International Journal of Chronic Obstructive Pulmonary Disease|April 10, 2019
AMPLIFY: a randomized, Phase III study evaluating the efficacy and safety of aclidinium/formoterol vs monocomponents and tiotropium in patients with moderate-to-very severe symptomatic COPDSanjay Sethi, Edward Kerwin, Henrik Watz, et al.
Respiratory Research|December 14, 2011
Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trialAnthony D'Urzo, Gary T Ferguson, Jan A van Noord, et al.
Journal of Asthma and Allergy|December 19, 2019
Two-Year Integrated Efficacy And Safety Analysis Of Benralizumab In Severe AsthmaJ Mark FitzGerald, Eugene R Bleecker, Arnaud Bourdin, et al.
COPD|October 30, 2009
Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomesAntonio Anzueto, Gary T Ferguson, Greg Feldman, et al.
Advances in Therapy|April 30, 2021
Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol Fumarate versus Other Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysisArnaud Bourdin, Nicolas Molinari, Gary T Ferguson, et al.
Journal of Managed Care & Specialty Pharmacy|May 3, 2023
Clinical and economic outcomes in patients with chronic obstructive pulmonary disease initiating maintenance therapy with tiotropium bromide/olodaterol or fluticasone furoate/umeclidinium/vilanterolSanjay Sethi, Swetha R Palli, Lindsay G S Bengtson, et al.
The New England Journal of Medicine|February 23, 2007
Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary diseasePeter M A Calverley, Julie A Anderson, Bartolome Celli, et al.
Chest|January 23, 2018
β-Blockers in COPD: A Cohort Study From the TONADO Research ProgramFrançois Maltais, Roland Buhl, Andrea Koch, et al.
Respiratory Medicine|June 25, 2021
Benefits of budesonide/glycopyrrolate/formoterol fumarate (BGF) on symptoms and quality of life in patients with COPD in the ETHOS trialFernando J Martinez, Klaus F Rabe, Gary T Ferguson, et al.
Pageof 11